DMT patents

 Owner/ApplicantPatent/Pub. No.TitlePriority DateStatusGeneral subject matter
1Gligamesh PharmaceuticalsWO2021168082A1Specific tryptamines for use in the treatment of mood disorders2020-02-18PublishedTryptamines for mood disorders; disclosing many and in vitro/in vivo data for four: N-methyl-N-ethyltryptamine, N-ethyl- N-propyltryptamine, and 5-fluoro analogs
2Yale University, U.S. Dep't of Veterans AffairsUS20210236523A1Psychedelic treatment for headache disorders2020-02-05Pending in USTreating a headache disorder by administering psilocybin, LSD, mescaline, DMT, DOI, DOB, and analogs thereof
3Synbionik GmbhWO2021110992A1Non-naturally occurring bacteria modified able to produce tryptophan derived compounds2019-12-04PublishedNon-naturally occurring microorganism modified to produce N,N-DMT and 5-MeO-DMT; methods of purifying it and formulating into pharmaceutical compositions
4Intima BioscienceWO2021067626A1Genetic engineering of fungi to modulate tryptamine expression2019-10-01PublishedMethods for modulating the tryptamine biosynthesis pathway and genetically modified organisms with induced and/or increased expression of tryptamines, including DMT
5CaaMTechUS20210023052A1Compositions containing toad secretion compounds2020-07-23Pending in USCompositions of (1) a purified toad secretion tryptamine, including N,N-DMT and 5-MeO-DMT, and (2) a serotonergic drug, psilocybin derivative, cannabinoid, or terpene
6Danmarks Tekniske UniversitetWO2021052989A1Yeast cells and methods for production of tryptophan derivatives2019-09-15PublishedTransformed cells capable of producing compounds including halogenated N,N-DMT, and methods of their use in production
7University of MarylandWO2021030571A1Methods of Treating Psychological and Brain Disorders2019-08-12PublishedMethods of treating a psychological disorder by administering a 5-HT agonist in combination with a 5-HT2A antagonist, the 5-HT agonists including DMT
8Applied Biology IncUS20210030787A1Methods for protecting hair follicles2019-07-31Pending in USTopical agents for reducing and inhibiting the effects of hair loss and hair shedding due to chemotherapy and radiotherapy, including by additionally using N,N-DMT
9Concept Matrix SolutionsUS20210015833A1Oral soft gel capsule containing psychedelic compound2019-07-18Pending in USSoftgels containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
10Concept Matrix SolutionsUS20210015738A1Oral dissolvable film containing psychedelic compound2019-07-17Pending in USFilms containing “psilocybin, psilocin, baeocystin, mescaline, LSD, ketamine, salvinorin A, ibotenic acid, muscimol, DMT, MDMA, MDEA, MDA, & combinations"
11GH Research LimitedWO2020254584A1Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) in methyl tert.-butyl ether (mtbe) and less than 5 wt% of an aliphatic anti-solvent2019-06-19PublishedMetholds of purifying 5-MeO-DMT and producing crystalline 5-MeO-DMT; compositions of purified 5-MeO-DMT
12Small Pharma LtdWO2021116503A2Deuterated compounds2019-06-03PublishedDeuterated N,N-DMT compounds and compositions, their use to treat psychiatric or neurological disorders, and their synthesis
13Small Pharma LtdWO2020245133A1Therapeutic Compositions Comprising Deuterated Or Partially Deuterated N,N-dimethyltryptamine Compounds2019-06-03PublishedCompositions comprising two or more of N,N-DMT and deuterated N,N-DMT compounds, their use to treat psychocognitive disorders, and their preparation
14Karl Dresdner, Michael Cary, Chase HudsonUS20200345585A1Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness2019-04-30Pending in USProcesses for making aqueous therapeutic nanoparticles, including with substituted tryptamines to treat depression, anxiety and PTSD, including N,N-DMT and 5-MeO-DMT
15The Regents Of The University Of CaliforniaWO2020185581A2Compositions And Methods For Modulating Lipid And Steroid Metabolism2019-03-08PublishedMethods for promoting colonization of spore-forming bacteria in a patient’s gut, comprising administering a serotonin receptor agonist, including N,N-DMT and 5-MeO-DMT
16University Of Padova, Institute For Research In Biomedicine, BarcelonaWO2020181194A1Compositions And Methods Of Use Comprising Substances With Neural Plasticity Actions Administered At Non-psychedelic/psychotomimetic Dosages And Formulations2019-03-07PublishedStructural analogues to psilocin, norpsilocin, psilocybin, baeocystin, norbaeocystin, and N,N-DMT, and their use as neuroplastogens and for microdosing
17GH Research LimitedWO2020169851A1Compositions Comprising 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) For Use In Treating Mental Disorders2019-02-22Published5-MeO-DMT for treatment of MDD where administered via intravenous, intramuscular or subcutaneous route
18GH Research LimitedWO2020169850A15-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) For Treating Depression2019-02-22Published5-MeO-DMT for treatment of MDD where administered via inhalation
19University of North Carolina at Chapel HillUS20200187851A1Periodontal disease stratification and uses thereof2018-12-17Pending in USMethods of treating and preventing periodontal disease and tooth loss, by administering a therapeutic agent, including 5-MeO-DMT
20Palo Alto Investors LPUS20200179349A1Methods of Treating Food Allergy Conditions2018-12-06Pending in USTreating a food allergy condition by administration of a psychedelic, including N,N-DMT and 5-MeO-DMT
21Neurolign USAWO2020097320A1Rehabilitation Of Subjects With Pharmacologically Induced Neuroplasticity2018-11-08Published"Neurological rehabilitation method" comprising performing tasks "during periods of pharmacologically induced neuroplasticity" including by administration of DMT
22RejoyUS20200060997A1TARR Receptor Agonists For Sexual Dysfunction2018-08-27Pending in USCompositions of a TARR receptor agonist for treating female sexual dysfunction, where it is applied to contract smooth muscle of the nipple areola complex, including of N,N-DMT
23Yale University, U.S. Dep't of Veterans AffairsWO2020041329A1Combination therapy for treating or preventing depression or other mood diseases2018-08-20PublishedTreating depression and mood disorders, with combination of a TOR inhibitor or immunosuppressant together with ketamine, psilocybin, LSD, ayahuasca, and DMT
24Applied Biology, Inc.WO2020023084A1Taar Receptor Agonists For The Treatment Of Alopecia2018-07-26PublishedMethods for treating hair shedding by applying a composition of a pilomotor effective amount of a Taar receptor agonist topically, including N,N-DMT
25Robert John PetcavichWO2019246532A1Method Of Inducing Dendritic And Synaptic Genesis In Neurodegenerative Chronic Diseases2018-06-21PublishedMethods of inducing neuron dendritic and synaptic genesis in neurodegenerative diseases by administering a tryptamine including N,N-DMT and 5-MeO-DMT
26Anavex Life Sciences Corp.WO2019222754A1Optimized Sigma-1 Agonist Method Of Responder Selection And Treatment2018-05-18PublishedMethods of selecting a subject having a genetic polymorphism causing the subject to have an altered response to a Sigma-1 receptor agonist, including where the agonist is DMT
27New Atlas Biotechnologies LLCUS20210108238A1Processes For The Production Of Tryptamines2018-03-08Pending in USProkaryotic and eukaryotic microbes, including E. coli and S. cerevisiae, genetically altered to biosynthesize tryptamines, including N,N-DMT and 5-MeO-DMT
28Akili Interactive LabsWO2019161050A1Cognitive Platform Including Computerized Elements Coupled With A Therapy For Mood Disorder2018-02-18PublishedComputer-implemented systems and methods for mood and cognitive assessment and treatment, including during psychedelic-assisted therapy with DMT
29Consejo Superior De Investigaciones Científicas (CSIC)WO2019081764A1Combination Product For The Treatment Of Neurological And/or Psychiatric Disorders2017-10-26PublishedCombination product comprising (1) psychedelic, including N,N-DMT and 5-MeO-DMT, and (2) a 5-HT2A receptor antagonist to prevent hallucinations
30EleusisWO2019079742A1Methods and systems for enhancing safety of psychedelic drug therapies2017-10-19PublishedScreening a candidate for treatment with psychedelic agent, including 5-MeO-DMT
31GW Research LtdUS20200237683A1Use Of Cannabidiol In Combination With 5-ht2b Receptor Agonists Or Amphetamins In The Treatment Of Epilepsy2017-09-29Pending in USCBD in combination with a 5-HT2B receptor agonist to treat epilepsy, including N,N-DMT and 5-MeO-DMT
32Bar-Ilan University, Ramot at Tel Aviv UniversityUS20200061076A1Methods Of Treating Leukodystrophies2017-05-11Pending in USMethods of treating leukodystrophy by administering an agent participating in Sigma-1 Receptor signaling pathway, including DMT
33EleusisUS20200147038A1Assessing and treating psychedelic-responsive subjects2017-04-20Pending in USImproving mental or physical well-being by administration of a psychedelic, including 5-MeO-DMT
34The Regents Of The University Of CaliforniaUS20200030309A1Compounds For Increasing Neural Plasticity2016-09-29Pending in USMethods for increasing neural plasticity by contacting a neuronal cell with a non-hallucinogenic analog of a psychedelic compound, including analogs of DMT
35Paul StametsUS20180021326A1Compositions and methods for enhancing neuro- regeneration and cognition by combining mushroom extracts containing [] psilocin or psilocybin with erinacines or hericenones enhanced with niacin2016-07-23AbandonedCompositions of niacin and mushroom or cannabis extracts, together with compounds including N,N-DMT and 5-MeO-DMT, and their use to improve neurological health
36Paul StametsUS20200375967Compositions of psilocybin and analogs2016-07-23Pending in USCompositions of niacin and mushroom or cannabis extracts, together with compounds including N,N-DMT and 5-MeO-DMT, and their use to improve neurological health
37Philip Morris ProductsUS10750785B2Aerosol-generating system comprising a bimetallic strip2015-03-27Granted 2020-08-25 (expires 2037-02-21)Vaporizer systems for delivery of a medicament, including N,N-DMT and 5-MeO-DMT
38Teva PharmaceuticalsWO2016138135A1Sigma-1 Receptor Modulators For Treating Huntington's Disease2015-02-25PublishedMethods of treating neurodegenerative diseases by administering a Sigma-1 receptor modulator, including N,N-DMT
39Syqe MedicalUS10118006B2Methods, devices and systems for pulmonary delivery of active agents2014-06-30Granted 2018-11-06 (expires 2035-06-30)Metered dose inhalers that monitor effects and their use to deliver pharmaceutically active agents including cannabinoids, salvinorin A, cocaine, psilocybin, and DMT
40Philip Morris ProductsUS10721963B2Electrically heated aerosol delivery system2013-05-21Granted 2020-07-28 (expires 2036-11-30)Vaporizer devices and cartridges for delivering an aerosolised medicament, including N,N-DMT and 5-MeO-DMT
41ALS Mountain LLCUS20140350064A1Pharmaceutical Composition Comprising An Ampk Activator And A Serotonergic Agent And Methods Of Use Thereof2013-03-15AbandonedPharmaceutical compositions of a AMPK activator and a serotonergic agent, the serotonergic agent including N,N-DMT and 5-MeO-DMT
42Harvard College, NIHUS20140221499A1Novel rodent control agents and uses thereof2011-06-16AbandonedMethods for controlling rodents by contacting the rodents with a compound which is a ligand for an olfactory TAAR receptor, including 5-MeO-DMT
43Syqe MedicalUS11071712B2Method and system for drug delivery2010-12-22Granted 2021-07-27Drug dose structure for use with an inhaler device having source material from which at least one active substance is released for delivery by vaporization, including DMT
44Syqe MedicalUS9775379B2Method and system for drug delivery2010-12-22Granted 2017-10-03
(expires 2034-09-26)
Inhaler device for controlled extraction of at least one active substance from at least one type of plant matter by application of heat, including DMT
45McMaster UniversityUS20130287705A1Method Of Treating Mucosal Inflammation2010-11-03AbandonedMethods of treating mucosal inflammation in the gastrointestinal tract, by administering 5-HT7 receptor antagonist, including N,N-DMT
46EaglePharma Pty LtdUS20130281401A1Combination Therapy For The Treatment Of Depression And Other Non-infectious Diseases2010-10-07AbandonedMethods of treating a non-infectious disease with combination of methylsulfonylmethane, glucosamine, L-glycine, and vitamin B12, and optionally additional agent, e.g., 5-MeO-DMT
47Emory UniversityUS20120108510A1Methods of improving behavioral therapies2010-05-20AbandonedPsychedelic-assisted psychotherapy using an oxytocin releasing agent, including N,N-DMT and 5-MeO-DMT
48Philip Morris ProductsUS9974743B2Device and method for delivery of a medicament2009-09-16Granted 2018-05-22 (expires 2034-02-26)Aerosol delivery devices for inhalation of nicotine, with disclosed uses for other compounds including N,N-DMT and 5-MeO-DMT
49LTS Lohmann Therapie Systeme GmbHUS10881607B2Composition For Transdermal Delivery Of Cationic Active Agents2008-06-19Granted 2021-01-05 (expires 2029-06-16)Transdermal patch with composition for transdermal delivery of at least one cationic active agent, including indole compounds such as N,N-DMT
50Fred Hutchinson Cancer Research CenterWO2009055001A2Methods Of Treating Aging And Methods Of Screening Candidate Agents Therefor2007-10-23PublishedMethods of treating aging by administering a 5-HT2 receptor antagonist, including DMT
51Mark T. Hamann et al.US8268856B2Method To Use Compositions Having Antidepressant Anxiolytic And Other Neurological Activity And Compositions Of Matter2007-10-09Granted 2012-09-18
(expires 2028-10-09)
Pharmaceutical formulations with antidepressant, anxiolytic, or antiobesity activity isolated from sea sponges, including 5-Bromo-DMT and 5,6-Dibromo-DMT
52Chelsea Therapeutics IncUS20130143868A1Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Mood Disorders, Sleep Disorders, Or Attention Deficit Disorders2007-05-07AbandonedMethods of treating ADD by administering droxidopa together with a second active agent, including 5-MeO-DMT
53Philip Morris Products (originally filed by Duke University)US10668058B2Device And Method For Delivery Of A Medicament2007-03-30Granted 2020-06-02
(expires 2029-02-09)
Aerosol delivery devices for inhalation of nicotine, with disclosed uses for other compounds including N,N-DMT and 5-MeO-DMT
54Chelsea Therapeutics IncUS20130116286A1Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Neurally Mediated Hypotension2007-03-12AbandonedMethods of treating neurally mediated hypotension by administering droxidopa together with a second active agent, the second agent including 5-MeO-DMT
55Chelsea Therapeutics IncUS8008285B2Droxidopa And Pharmaceutical Composition Thereof For The Treatment Of Fibromyalgia2007-03-09Granted 2011-08-30 (expires 2029-02-16)Methods of treating fibromyalgia by administering droxidopa together with a second active agent, the second agent including 5-MeO-DMT
56Chien-Hung ChenUS20120183600A1Novel Composition For Treating Metabolic Syndrome And Other Conditions2007-01-16AbandonedCompositions of an oxidative phosphorylation inhibitor, ionophore, or AMPK activator; an anti-inflammatory agent; and a serotonergic agent, including N,N-DMT and 5-MeO-DMT
57Lundbeck NA LtdUS20160106694A1Pharmaceutical Compositions Comprising Droxidopa2006-06-28AbandonedPharmaceutical compositions of droxidopa in combination with one or more additional compounds for increasing its half-life, including 5-MeO-DMT
58Bioniqs LimitedWO2007110637A1Method For Extracting Target Alkaloid Using An Ionic Liquid As Extracting Solvent2006-03-28PublishedMethods for extracting a target alkaloid from a mixture of species, by using an ionic liquid as an extracting solvent, including for N,N-DMT and 5-MeO-DMT
59PLT Patent and License Trading LtdUS20100143322A1Use Of Inhibitors Of N-methyl Transferases For The Therapy Of Parkinson's Disease2005-06-24AbandonedMethods for treating Parkinson's with exogenic or endogenic inhibitors of N-methyl transferases, including N,N-DMT
60Virginia Commonwealth UniversityUS6518297B2Selective 5-ht6 Receptor Ligands2001-08-20Granted 2003-02-11 (expired 2019-12-10)Treating mental disorders mediated by the 5-HT6 receptor by administering tryptamine derivatives, including 2-ethyl-5-MeO-DMT, and 5-MeO-2-phenyl-N,N-DMT
61Sigma Tau Industrie Farmaceutiche Riunite SpAUS7098233B25-halo-tryptamine Derivatives Used As Ligands On The 5-ht6 And/or 5-ht7 Serotonin Receptors2001-06-21Granted 2006-08-29 (expires 2022-06-17)Methods of interacting with 5-HT6 and 5-HT7 receptors by administering tryptamine derivatives including 5-bromo-2-methyl- and 5-bromo-2-ethyl-N,N-DMT
62Psychiatric Genomics IncUS7132287B2Method For Neural Stem Cell Differentiation Using 5ht-1a Agonists2001-06-18Granted 2006-11-07 (expires 2023-02-23)Methods for differentiating neural stem cells into a neuronal cell such as a neuroblast or a neuron in vitro or in vivo by contacting with a 5HT1A ligand, including 5-MeO-DMT
63Alcon Laboratories IncWO1998018458A1Opthalmological Compositions Containing Serotonin 5-ht1a Receptor Agonist And Their Use In The Treatment Of Glaucoma1996-10-31PublishedOphthalmic compositions for controlling intraocular pressure with a 5-HT1A receptor agonist that inhibits adenylyl cyclase, including 5-MeO-DMT
64Nosrat E. NaftchiUS4742054ATreatment of mammals suffering from damage to the central nervous system1982-11-23Granted 1988-05-03
(expired 2005-05-03)
Methods for treating a mammal having an injured spinal cord and loss of motor and sensory function by administering a neural receptor agonist, including 5-MeO-DMT